Communiqués Ultragenyx Pharmaceutical Inc.

Actions

RARE

US90400D1081

Produits pharmaceutiques

Temps réel estimé 21:59:04 18/08/2026 Varia. 5j. Varia. 1 janv.
25,47 USD -2,53% Graphique intraday de Ultragenyx Pharmaceutical Inc. -5,34% +10,96%

Communiqués

04/08 Ultragenyx: Q2 Earnings Snapshot AQ
04/08 Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update GL
28/07 Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update GL
28/07 Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update AQ
24/07 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
08/07 Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact GL
22/06 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) AQ
19/06 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
03/06 Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference GL
01/06 Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm NE
22/05 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
06/05 Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference GL
05/05 Ultragenyx: Q1 Earnings Snapshot AQ
05/05 Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update GL
29/04 Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update GL
27/04 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) AQ
24/04 Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GL
08/04 RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 NE
05/04 RARE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 NE
04/04 Ultragenyx 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE BU
03/04 DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026 PR
02/04 Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) GL
31/03 Ultragenyx Announces FDA Clearance of Investigational New Drug Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy AQ
31/03 RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 NE
30/03 NASDAQ: RARE CLASS ACTION NOTICE: Berger Montague Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire About a Securities Fraud Class Action NE
Aucun résultat pour cette recherche